MedTrace Logo

Effect of Liraglutide on Weight and Appetite in Obese Subjects With Type 2 Diabetes

NCT01508949 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2023-11-02

No results posted yet for this study

Summary

This trial is conducted in Europe. The aim of the trial is to investigate the effect of NNC 90-1170 (liraglutide) on weight and appetite in obese subjects with type 2 diabetes treated with diet and/or sulphonylurea or repaglinide.

Conditions

Interventions

DRUG

liraglutide

Once daily dosing of 0.6 mg for 8 weeks, injected subcutaneously

DRUG

placebo

Once daily dosing of 0.6 mg for 8 weeks, injected subcutaneously

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-06-30
Primary Completion
2002-03-31
Completion
2002-03-31

Countries

  • Denmark

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01508949 on ClinicalTrials.gov